Education
About Us
Working with TipRanks
Follow Us
Eterna Therapeutics (ERNA)
NASDAQ:ERNA
ERNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.33 - $28.65
Previous Close$0.34
Volume440.10K
Average Volume (3M)72.61K
Market Cap
$10.20M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.26
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.21
Shares Outstanding7,670,889
10 Day Avg. Volume47,521
30 Day Avg. Volume72,609
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Eterna Therapeutics News
ERNA FAQ
What was Eterna Therapeutics’s price range in the past 12 months?
Eterna Therapeutics lowest stock price was $1.33 and its highest was $28.65 in the past 12 months.
What is Eterna Therapeutics’s market cap?
Eterna Therapeutics’s market cap is $10.20M.
When is Eterna Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Eterna Therapeutics’s earnings last quarter?
Currently, no data Available
Is Eterna Therapeutics overvalued?
According to Wall Street analysts Eterna Therapeutics’s price is currently Overvalued.
Does Eterna Therapeutics pay dividends?
Eterna Therapeutics does not currently pay dividends.
What is Eterna Therapeutics’s EPS estimate?
Eterna Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eterna Therapeutics have?
Eterna Therapeutics has 7,670,889 shares outstanding.
What happened to Eterna Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eterna Therapeutics?
Currently, no hedge funds are holding shares in ERNA
Eterna Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.15%
12-Months-Change
Fundamentals
Return on Equity
-2264.31%
Trailing 12-Months
Asset Growth
-83.69%
Trailing 12-Months
Company Description
Eterna Therapeutics
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Eterna Therapeutics (ERNA) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Plus Therapeutics
―
Minerva Neurosciences
―
Affimed
―
GeoVax Labs
―
Addex Therapeutics
―
Ownership Overview
32.72% Insiders
0.45% Mutual Funds
0.76% Other Institutional Investors
66.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---